Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2460 November 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
Fax Number:Inotuzumab ozogamicin		Fax Number:
Initial application Applications only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months. Prerequisites(tick boxes where appropriate) Patient has relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia/lymphoma, including minimal residual disease Patient has ECOG performance status of 0-2 and Patient has Philadelphia chromosome positive B-Cell ALL and Patient has previously received a tyrosine kinase inhibitor or Patient has received one prior line of treatment involving intensive chemotherapy and Treatment is to be administered for a maximum of 3 cycles		
Prerequisites(tick boxes where appropriate) Patient is not proceeding to a stem and Patient has experienced com or	relevant practitioner on the recommendation of a rele	
Treatment with inotuzumab ozogan	micin is to cease after a total duration of 6 cycles	

I confirm the above details are correct and that in signing this form I understand I may be audited.